These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25211304)

  • 1. Miltefosine (Impavido) for leishmaniasis.
    Med Lett Drugs Ther; 2014 Sep; 56(1451):89-90. PubMed ID: 25211304
    [No Abstract]   [Full Text] [Related]  

  • 2. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Miltefosine (Impavido): the first oral treatment against leishmaniasis.
    Sindermann H; Croft SL; Engel KR; Bommer W; Eibl HJ; Unger C; Engel J
    Med Microbiol Immunol; 2004 Nov; 193(4):173-80. PubMed ID: 14513375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal leishmaniasis and miltefosine.
    Tuon FF; Amato VS
    Clin Infect Dis; 2007 Jun; 44(11):1525-6; author reply 1526-7. PubMed ID: 17479959
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral miltefosine to treat new world cutaneous leishmaniasis.
    Soto J; Toledo JT
    Lancet Infect Dis; 2007 Jan; 7(1):7. PubMed ID: 17182338
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 7. Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment.
    Tappe D; Müller A; Stich A
    Am J Trop Med Hyg; 2010 Jan; 82(1):1-3. PubMed ID: 20064985
    [No Abstract]   [Full Text] [Related]  

  • 8. Miltefosine: oral treatment of leishmaniasis.
    Soto J; Soto P
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miltefosine--the long-awaited therapy for visceral leishmaniasis?
    Herwaldt BL
    N Engl J Med; 1999 Dec; 341(24):1840-2. PubMed ID: 10588972
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
    Ruiz-Villaverde R; Sánchez-Cano D; Villaverde-Gutierrez C
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):695-6. PubMed ID: 17447994
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.
    Vakil NH; Fujinami N; Shah PJ
    Pharmacotherapy; 2015 May; 35(5):536-45. PubMed ID: 25940658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miltefosine and cutaneous leishmaniasis.
    Machado PR; Penna G
    Curr Opin Infect Dis; 2012 Apr; 25(2):141-4. PubMed ID: 22248979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
    Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
    J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
    Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
    Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miltefosine for new world cutaneous leishmaniasis.
    Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
    Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.
    Soto J; Rea J; Valderrama M; Toledo J; Valda L; Ardiles J; Berman J
    Am J Trop Med Hyg; 2009 Sep; 81(3):387-9. PubMed ID: 19706901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapy for "black fever" is 95% effective: India licenses the first oral drug for visceral leishmaniasis, a lethal disease of poverty.
    Indian J Med Sci; 2002 Sep; 56(9):454-6. PubMed ID: 12710345
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
    Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
    Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
    Sindermann H; Engel KR; Fischer C; Bommer W;
    Clin Infect Dis; 2004 Nov; 39(10):1520-3. PubMed ID: 15546090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascorbic acid reduces the genetic damage caused by miltefosine (hexadecylphosphocholine) in animals infected by Leishmania (Leishamnia) infantum without decreasing its antileishmanial activity.
    Castelo-Branco PV; Alves HJ; Pontes RL; Maciel-Silva VL; Ferreira Pereira SR
    Int J Parasitol Drugs Drug Resist; 2019 Apr; 9():8-15. PubMed ID: 30578864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.